Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More

Executive Summary

Califf was candid during an FDA Science Board meeting about the agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.

You may also be interested in...



Herbalife Executives' Investments Spark Uptick In Share Price After Results Send Stock Plummeting

Since closing at a 14-year low of $8.07 the day of the execs’ transactions, Herbalife shares trend steadily up from close of $8.26 on 20 February to $8.83 on 29 February. Some execs sell back some shares on 25 February at $8.67.

Infant Formula Production Expansion Brings Problems Souring Perrigo's 2024 Forecast

Perrigo doesn’t attempt to diminish significance of challenge to regain sales growth in formula market as it resets its plants. Analysts see formula business as only current impediment to stronger results.

Perrigo Delivering Opill Sales Within A Month, Launches ‘Energize’ Efficiency Project Immediately

Perrigo says 2024 results will be slowed by investment in companywide efficiency project including staff reductions. After Opill’s expected launch by late March, sales will be dilutive to earnings for the first year partly due to investments in the brand, primarily at retailers and online in Q2.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel